Peter Hoehn, Accomplished Pharmaceutical Executive, Joins Cohen Veterans Bioscience (CVB) in Newly Created Executive Leadership Role

Peter Hoehn joins Cohen Veterans Bioscience (CVB) as Executive Vice President, Strategic Marketing, Development, and Impact. In this newly created role, Hoehn will lead the External Affairs, Communications, and Development functions for New York-based non-profit CVB which is dedicated to advancing brain health.

Peter Hoehn joins Cohen Veterans Bioscience (CVB) as Executive Vice President, Strategic Marketing, Development, and Impact. In this newly created role, Hoehn will lead the External Affairs, Communications, and Development functions for New York-based non-profit CVB which is dedicated to advancing brain health. Hoehn will report to CVB Founder, CEO and President Dr. Magali Haas, MD, PhD.

Peter Hoehn is a proven healthcare business leader with 25+ years’ experience in a variety of commercial and strategy roles, predominantly at Johnson & Johnson. Hoehn was most recently Head, Commercial Strategy for J&J Science for Minds, a new organization focused on innovative development models and digital solutions to address serious mental illness and dementia. In this position he developed the strategy, portfolio recommendations, investment approach, external collaborations, and business models for new mental health and brain health digital business ventures.

“We are thrilled to have Peter join CVB in this new and important leadership role. I have had the privilege of partnering with Peter to advance brain therapeutics during our joint tenure at Johnson & Johnson and, more recently, in his capacity on the Steering Committee of the CVB-led Brain Health Nexus initiative. I am certain he will add impactful healthcare business expertise to our organization at a time of intense growth and development,” said Dr. Haas.

Throughout his career Peter has demonstrated the ability to develop insight-driven strategies in complex markets and mobilize internal and external partners to achieve results. He brings broad-based commercial, strategy and leadership experiences across Pharmaceuticals, Diagnostics, Digital Health, and Precision Medicine, including brand positioning and messaging, reimbursement and market access, global launches, organizational capability building, business model innovation, new opportunity evaluation, business development, and policy.

Peter started his career as a corporate lawyer and entered the pharmaceutical industry as an attorney for Bristol Myers Squibb. After a short time as a lawyer Peter moved into various strategy, marketing, and sales management roles at BMS before joining Johnson & Johnson in 2003.

Peter received a BA in Government and Economics from the College of William and Mary, and a JD from New York University.

View this press release on PR Newswire

Share this article:

More from CVB

https://www.cohenveteransbioscience.org/wp-content/uploads/2023/05/CVB-PR_MM-matt_mitchell_quote-1200x670-1.jpg

Cohen Veterans Bioscience Joins Veteran Matthew Mitchell on Military Makeover with Montel to Discuss Traumatic Brain Injury

https://www.cohenveteransbioscience.org/wp-content/uploads/2022/11/cvb-22-jumps-2.jpg

Cohen Veterans Bioscience and 22 Jumps Announce Parachuting with Purpose: Recognizing the Epidemic of Veterans Suicide as a Result of Traumatic Brain Injury (TBI) and PTSD

https://www.cohenveteransbioscience.org/wp-content/uploads/2023/03/2023-best-negative-data-prize-clinical-neuroscience-featured_image.jpg

Cohen Veterans Bioscience and the European College of Neuropsychopharmacology Announce the 2023 Best Negative Data Prize in Clinical Neuroscience

About Cohen Veterans Bioscience (CVB)

Cohen Veterans Bioscience is a non-profit 501(c)(3) biomedical research and technology organization dedicated to advancing brain health by fast-tracking precision diagnostics and tailored therapeutics.

For Media Inquiries

Please feel free to email us at media@cohenbio.org